221 related articles for article (PubMed ID: 36798518)
1. Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA.
Stolovich-Rain M; Kumari S; Friedman A; Kirillov S; Socol Y; Billan M; Pal RR; Das K; Golding P; Oiknine-Djian E; Sirhan S; Sagie MB; Cohen-Kfir E; Gold N; Fahoum J; Kumar M; Elgrably-Weiss M; Zhou B; Ravins M; Gatt YE; Bhattacharya S; Zelig O; Wiener R; Wolf DG; Elinav H; Strahilevitz J; Padawer D; Baraz L; Rouvinski A
Front Immunol; 2022; 13():933347. PubMed ID: 36798518
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva.
Winklmeier S; Rübsamen H; Özdemir C; Wratil PR; Lupoli G; Stern M; Schneider C; Eisenhut K; Ho S; Wong HK; Taskin D; Petry M; Weigand M; Eichhorn P; Foesel BU; Mader S; Keppler OT; Kümpfel T; Meinl E
Front Immunol; 2024; 15():1330864. PubMed ID: 38375482
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection.
Schmidt KG; Harrer EG; Tascilar K; Kübel S; El Kenz B; Hartmann F; Simon D; Schett G; Nganou-Makamdop K; Harrer T
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337058
[TBL] [Abstract][Full Text] [Related]
5. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
6. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Maurino V; Baj A; Gianfagna F; Cavallo P; Dentali F; Tettamanti L; Maggi F; Maffioli LS; Tagliabue A; Accolla RS; Forlani G
EBioMedicine; 2023 Feb; 88():104435. PubMed ID: 36628844
[TBL] [Abstract][Full Text] [Related]
8. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
Focosi D; Maggi F; Casadevall A
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
[TBL] [Abstract][Full Text] [Related]
9. Development of an Oral IgA Response against SARS-CoV-2 Following Immunization with Different COVID-19 Vaccines.
Soffritti I; D'Accolti M; Bini F; Mazziga E; Proietto D; Dallan B; Laurentis M; Ghisellini S; Nicoli F; Caselli E
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140560
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
11. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
12. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
13. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
14. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
Carreño JM; Raskin A; Singh G; Tcheou J; Kawabata H; Gleason C; Srivastava K; Vigdorovich V; Dambrauskas N; Gupta SL; González Domínguez I; Martinez JL; Slamanig S; Sather DN; Raghunandan R; Wirachwong P; Muangnoicharoen S; Pitisuttithum P; Wrammert J; Suthar MS; Sun W; Palese P; García-Sastre A; Simon V; Krammer F
Sci Transl Med; 2023 Feb; 15(683):eabo2847. PubMed ID: 36791207
[TBL] [Abstract][Full Text] [Related]
15. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
16. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
17. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.
Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A
Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935
[TBL] [Abstract][Full Text] [Related]
18. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Darwich A; Pozzi C; Fornasa G; Lizier M; Azzolini E; Spadoni I; Carli F; Voza A; Desai A; Ferrero C; Germagnoli L; ; Mantovani A; Rescigno M
EMBO Mol Med; 2022 May; 14(5):e15326. PubMed ID: 35393790
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
20. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
